Moreover, recombinant human NGF (rhNGF) eye drops, such as Cenegermin (OxervateTM), have already been formulated and approved in the Unites States for the treatment of corneal ulcers (Ahuja et al., 2020), although they have not yet been approved in the European Union. Here, NGF is linked to corneal infection.